Contract Research and Manufacturing Services (CRAMS)

Contract Research and Manufacturing Services (CRAMS)

Global Contract Research and Manufacturing Services (CRAMS) Market to Reach US$211.4 Billion by 2030

The global market for Contract Research and Manufacturing Services (CRAMS) estimated at US$128.8 Billion in the year 2023, is expected to reach US$211.4 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2023-2030. Manufacturing Service, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$126.8 Billion by the end of the analysis period. Growth in the Research Service segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$35.1 Billion While China is Forecast to Grow at 11.5% CAGR

The Contract Research and Manufacturing Services (CRAMS) market in the U.S. is estimated at US$35.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$46.5 Billion by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Contract Research and Manufacturing Services (CRAMS) Market - Key Trends and Drivers Summarized

Contract Research and Manufacturing Services (CRAMS) encompass a broad spectrum of outsourcing services provided by companies to the pharmaceutical and biotechnological sectors. CRAMS allow drug developers to delegate specific R&D processes and manufacturing tasks to external partners. These services cover a wide range of activities, from early-stage drug discovery, preclinical trials, and clinical research to large-scale commercial manufacturing and API (active pharmaceutical ingredient) production. By leveraging CRAMS, pharmaceutical companies can significantly reduce capital investment and operational costs, streamline product development timelines, and enhance flexibility in managing the fluctuating demands of drug development and production. Moreover, CRAMS providers offer specialized expertise and advanced facilities that many pharmaceutical companies might not possess internally, making them an integral component of today’s drug development landscape.

The CRAMS industry has adapted to meet the evolving needs of the global healthcare sector, focusing on flexibility, scalability, and state-of-the-art technological integration. As biopharmaceutical products become more complex, the demand for sophisticated and specialized manufacturing techniques has escalated. CRAMS providers have responded by investing in cutting-edge technologies such as continuous manufacturing and bioreactors, which are crucial for the production of biologics and advanced therapy medicinal products (ATMPs), including gene and cell therapies. This trend is supported by a move towards more personalized medicine approaches, which require the production of small batches of highly specialized drugs. Furthermore, CRAMS providers have developed strong regulatory expertise to navigate the complex and varying global regulatory landscapes, ensuring compliance and facilitating smoother market entries for new drugs.

The growth in the CRAMS market is driven by several factors, including the increasing complexity of pharmaceutical production, heightened cost pressures faced by drug developers, and a surge in the number of small to mid-size biotech companies. Technological advancements in drug development processes have necessitated the adoption of highly specialized manufacturing capabilities that many pharmaceutical companies do not have in-house. This has increased their reliance on CRAMS providers who possess the necessary technological infrastructure and expertise. Additionally, the rising focus on cost-efficiency within the pharmaceutical industry has propelled companies to seek external partners that can provide economies of scale and scope in both research and production phases. Consumer behavior has also influenced the CRAMS market, particularly as there is an increasing demand for faster development and delivery of new therapies to the market, which CRAMS can facilitate. Moreover, the growth of the biologics sector, which requires distinct production environments and expertise, continues to drive the expansion of CRAMS, making it an essential component of the modern pharmaceutical supply chain.

Select Competitors (Total 86 Featured) -

• AbbVie Inc.
• Arch Pharmalabs Ltd.
• Calyx Chemicals and Pharmaceuticals Ltd.
• Globela Pharma Pvt. Ltd.
• Ind-Swift Laboratories Ltd.
• Merck KGaA,
• MSN Laboratories
• Murli Krishna Pharma Private Ltd.
• Novartis AG
• Orchid Pharma Ltd.
• SMS Pharmaceuticals Ltd.
• Sun Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Ultratech India Limited
• VIVAN Life Sciences Pvt Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.